Cargando…
From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy
Background: In the last decade, a series of analyses failed to identify predictive biomarkers of resistance/susceptibility for anti-angiogenic drugs in metastatic colorectal cancer (mCRC). We conducted an exploratory preplanned analysis of serum pro-angiogenic factors (SErum aNgiogenesis-cenTRAL) in...
Autores principales: | Giampieri, Riccardo, Ziranu, Pina, Daniele, Bruno, Zizzi, Antonio, Ferrari, Daris, Lonardi, Sara, Zaniboni, Alberto, Cavanna, Luigi, Rosati, Gerardo, Casagrande, Mariaelena, Pella, Nicoletta, Demurtas, Laura, Zampino, Maria Giulia, Sozzi, Pietro, Pusceddu, Valeria, Germano, Domenico, Lai, Eleonora, Zagonel, Vittorina, Codecà, Carla, Libertini, Michela, Puzzoni, Marco, Labianca, Roberto, Cascinu, Stefano, Scartozzi, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281010/ https://www.ncbi.nlm.nih.gov/pubmed/32456056 http://dx.doi.org/10.3390/cancers12051330 |
Ejemplares similares
-
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial
por: Giampieri, Riccardo, et al.
Publicado: (2017) -
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab
por: Demurtas, Laura, et al.
Publicado: (2017) -
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
por: Ziranu, Pina, et al.
Publicado: (2021) -
Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not?
por: Pretta, Andrea, et al.
Publicado: (2022) -
How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world
por: Pretta, Andrea, et al.
Publicado: (2022)